The decision hands Moderna its second-only product approval to date after its Covid jab, which has generated more than $40bn in revenue. Its blockbuster Covid shot propelled the Boston-based ...
Synopsys VC Verification IP (VIP) for Fibre Channel is designed to thoroughly verify Fibre Channel designs using both random and directed simulation. The Fibre Channel VIP provides full protocol ...
Synthesia's new technology is impressive but raises big questions about a world where we increasingly can’t tell what’s real. The FDA is poised to approve the notorious party drug as a therapy. Here’s ...
Moderna Inc. gained US approval for its RSV vaccine in older adults, giving the biotech company a second product as it seeks to move beyond its reliance on the fading market for Covid-19 shots ...
Moderna Inc.’s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said Friday, marking the first time a messenger RNA vaccine has been approved ...
Moderna's RSV shot is the first messenger RNA-based (mRNA) vaccine not for COVID-19 to be approved in the United States. It will be sold under the brand name mRESVIA The company has said mRNA ...
The facility, which will be the drugmaker's first end-to-end ADC production site, will be supported by the Singapore Economic Development Board. The company did not provide details on the possible ...
A researcher at the Moderna headquarters in Cambridge, Mass. (Adam Glanzman/Bloomberg News) Moderna, the biotech that rose to fame for making one of the world’s first Covid-19 vaccines ...
Moderna plans to compete. It will have to, as declining sales of its popular COVID vaccine have put pressure on the company to deliver growth from other products. Like its COVID shot, mResvia is ...
Covid-19 cases are relatively low right ... The company said it could get the shot to US warehouses by August. Pfizer and Moderna’s mRNA vaccines can be developed more quickly, and those ...
With the acute phase of the Covid-19 pandemic fading even as the coronavirus ... By Pam Belluck Experts say cases could rise in the coming weeks. Here’s what to know about symptoms, testing ...